Structureactivity relationship of ENL-driven CRBN binding To evaluate the mechanism of CRBN engagement further, we assessed the dHTC1 structureactivity relationship (SAR) by replacing the sulfamide connection with an amide, yielding rac -dHTC1-amide ( 5 ), or with a urea, yielding rac -dHTC1-urea ( 6 )

Research Dose Ranges Preclinical animal studies: 110 mcg/kg (nanogram to microgram range) once or twice daily Extrapolated human equivalent range commonly discussed in clinical literature: 200500 mcg/day Human pilot IV data: doses up to 20 mg were tolerated without adverse effects in two healthy adults (Lee & Burgess, 2025) though this is far above typical outpatient dosing Protocol: Musculoskeletal / Connective Tissue Healing For tendon, ligament, or muscle injury recovery, the standard approach in clinical functional medicine practice involves: SubQ injection at 200500 mcg once daily , injected near (not into) the injury site Cycle length: typically 48 weeks , with reassessment Often combined with TB-500 (thymosin beta-4) for synergistic tissue remodeling the BPC+TB stack Best results seen alongside physical therapy, not as a substitute for it Protocol: Gut and GI Mucosal Healing For IBD, gut permeability, NSAID damage, or H
and Lavandula stoechas L
A SNP on GABRA2 (GABA receptor) is associated with to lower activity and therefore reduced sensitivity to GABA